羟苯磺酸钙联合复方血栓通胶囊治疗糖尿病性视网膜病变患者的临床疗效
|
摘要
目的探讨羟苯磺酸钙联合复方血栓通胶囊治疗糖尿病性视网膜病变患者的临床疗效。方法随机选取2016年7月—2018年7月该院收治的糖尿病性视网膜病变患者60例,然后平均分成两组,将入组患者按先后序列号(1～60)随机分为2组:一组羟苯磺酸钙联合复方血栓通胶囊治疗组(联合治疗组,30例),一组单独复方血栓通胶囊治疗组(单独治疗组,30例),统计分析两组患者的视力、视野灰度值、黄斑厚度、出血斑面积、血管瘤体积、临床疗效、不良反应发生情况及复发情况。结果联合治疗组患者的LogMAR视力、视野灰度值、黄斑厚度、出血斑面积、血管瘤体积(0.31±0.05)、(1.2±0.3)%、(302.0±45.2)μm、(1.1±0.3)mm2、(10.0±2.3)μm3均显著低于单独治疗组(0.44±0.04)、(2.5±0.3)%、(350.3±47.0)μm、(1.9±0.4)mm2、(14.1±2.7)μm3(t=4.303,3.182,2.776,2.571,2.447,P<0.05),治疗的总有效率93.3%(28/30)显著高于单独治疗组70.0%(21/30)(χ~2=12.83,P<0.05),复发率3.3%(1/30)显著低于单独治疗组16.7%(5/30)(χ~2=9.35,P<0.05)。结论羟苯磺酸钙联合复方血栓通胶囊治疗糖尿病性视网膜病变患者的临床疗效较单独复方血栓通胶囊治疗显著,值得在临床推广。
Objective To investigate the clinical efficacy of calcium dobesilate combined with Compound Xueshuantong Capsule in the treatment of diabetic retinopathy. Methods 60 patients with diabetic retinopathy admitted to our hospital from July 2016 to July 2018 were randomly selected and divided into two groups. randomly divide the patients into consecutive groups(1-60). Group 2: a group of calcium hydroxybenzenesulfonate combined with compound Xueshuantong capsule treatment group(30 cases in combination therapy group), a group of compound Xueshuantong capsule treatment group(alone treatment group, 30 cases), statistical analysis of two groups of patients visual acuity, visual field gray value, macular thickness, hemorrhagic plaque area, hemangioma volume, clinical efficacy, adverse reactions and recurrence. Results LogMAR visual acuity, visual field gray value, macular thickness, hemorrhage area, hemangioma volume(0.31 ±0.05),(1.2±0.3)%,(302.0±45.2)μm,(1.1±0.3) mm2,(10.0±2.3) μm3 in the combined treatment group, were significantly lower than the treatment groups alone(0.44±0.04),(2.5±0.3)%,(350.3±47.0)μm,(1.9±0.4)mm2,(14.1±2.7)μm3(t= 4.303, 3.182, 2.776, 2.571,2.447, P<0.05), the total effective rate of treatment was 93.3%(28/30) significantly higher than that of the treatment group alone 70.0%(21/30)(χ~2=12.83, P<0.05), The recurrence rate of 3.3%(1/30) was significantly lower than that of the treatment group(16.7%, 5/30)(χ~2=9.35, P<0.05). Conclusion The clinical efficacy of calcium hydroxybenzenesulfonate combined with compound Xueshuantong Capsule in the treatment of diabetic retinopathy is more significant than that of compound Xueshuantong capsule alone. It is worthy of clinical promotion.
Objective To investigate the clinical efficacy of calcium dobesilate combined with Compound Xueshuantong Capsule in the treatment of diabetic retinopathy. Methods 60 patients with diabetic retinopathy admitted to our hospital from July 2016 to July 2018 were randomly selected and divided into two groups. randomly divide the patients into consecutive groups(1-60). Group 2: a group of calcium hydroxybenzenesulfonate combined with compound Xueshuantong capsule treatment group(30 cases in combination therapy group), a group of compound Xueshuantong capsule treatment group(alone treatment group, 30 cases), statistical analysis of two groups of patients visual acuity, visual field gray value, macular thickness, hemorrhagic plaque area, hemangioma volume, clinical efficacy, adverse reactions and recurrence. Results LogMAR visual acuity, visual field gray value, macular thickness, hemorrhage area, hemangioma volume(0.31 ±0.05),(1.2±0.3)%,(302.0±45.2)μm,(1.1±0.3) mm2,(10.0±2.3) μm3 in the combined treatment group, were significantly lower than the treatment groups alone(0.44±0.04),(2.5±0.3)%,(350.3±47.0)μm,(1.9±0.4)mm2,(14.1±2.7)μm3(t= 4.303, 3.182, 2.776, 2.571,2.447, P<0.05), the total effective rate of treatment was 93.3%(28/30) significantly higher than that of the treatment group alone 70.0%(21/30)(χ~2=12.83, P<0.05), The recurrence rate of 3.3%(1/30) was significantly lower than that of the treatment group(16.7%, 5/30)(χ~2=9.35, P<0.05). Conclusion The clinical efficacy of calcium hydroxybenzenesulfonate combined with compound Xueshuantong Capsule in the treatment of diabetic retinopathy is more significant than that of compound Xueshuantong capsule alone. It is worthy of clinical promotion.
引文
[1]蔡玲敏,黄锦林,卢益丽,等.羟苯磺酸钙联合复方血栓通胶囊治疗糖尿病性视网膜病变患者的临床效果[J].中国生化药物杂志,2017,37(3):228-230.
[2]艾薇.羟苯磺酸钙联合复方血栓通胶囊治疗糖尿病性视网膜病变的价值[J].中国保健营养,2017,27(35):129.
[3]喻巍,林柏松,马淑凤,等.羟苯磺酸钙联合复方血栓通胶囊治疗早期糖尿病性视网膜病变的疗效及对血清IGF-1和VEGF水平的影响[J].中国老年学杂志,2017,37(21):5311-5313.
[4]马京平.复方血栓通胶囊联合羟苯磺酸钙治疗早期糖尿病性视网膜病变[J].国际眼科杂志,2018,18(2):305-308.
[5]赵燕,吴建华,严立,等.复方血栓通胶囊联合羟苯磺酸钙治疗非增生性糖尿病性视网膜病变的疗效[J].国际眼科杂志,2017,17(11):2147-2150.
[6]罗慧娟,吴远松.羟苯磺酸钙胶囊联合复方血栓通胶囊治疗玻璃体积血的疗效观察[J].中国医院用药评价与分析,2018,18(2):182-184.
[7]张招德.康柏西普辅助玻璃体手术治疗增殖性糖尿病性视网膜病变的临床疗效[J].中外医疗,2016,35(36):73-75.
[8]马鹏天,方朝晖,陈义,等.丹蛭胶囊联合激光治疗糖尿病性视网膜病变78例[J].中外医疗,2011,30(1):51-52.
[2]艾薇.羟苯磺酸钙联合复方血栓通胶囊治疗糖尿病性视网膜病变的价值[J].中国保健营养,2017,27(35):129.
[3]喻巍,林柏松,马淑凤,等.羟苯磺酸钙联合复方血栓通胶囊治疗早期糖尿病性视网膜病变的疗效及对血清IGF-1和VEGF水平的影响[J].中国老年学杂志,2017,37(21):5311-5313.
[4]马京平.复方血栓通胶囊联合羟苯磺酸钙治疗早期糖尿病性视网膜病变[J].国际眼科杂志,2018,18(2):305-308.
[5]赵燕,吴建华,严立,等.复方血栓通胶囊联合羟苯磺酸钙治疗非增生性糖尿病性视网膜病变的疗效[J].国际眼科杂志,2017,17(11):2147-2150.
[6]罗慧娟,吴远松.羟苯磺酸钙胶囊联合复方血栓通胶囊治疗玻璃体积血的疗效观察[J].中国医院用药评价与分析,2018,18(2):182-184.
[7]张招德.康柏西普辅助玻璃体手术治疗增殖性糖尿病性视网膜病变的临床疗效[J].中外医疗,2016,35(36):73-75.
[8]马鹏天,方朝晖,陈义,等.丹蛭胶囊联合激光治疗糖尿病性视网膜病变78例[J].中外医疗,2011,30(1):51-52.